NeuroSense Therapeutics
NRSN
7 hedge funds and large institutions have $286K invested in NeuroSense Therapeutics in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 7 → 7 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
8.11% less ownership
Funds ownership: 9.26% → 1.16% (-8.1%)
85% less capital invested
Capital invested by funds: $1.87M → $286K (-$1.59M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$75.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$12.7K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$12K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.77M |
| 2 |
Morgan Stanley
New York
|
-$1.68K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$60 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CF
1
Cantor Fitzgerald
New York
| $101K | +$75.6K | +79,492 | New |
|
|
XT
2
XTX Topco
George Town,
Cayman Islands
| $58.4K | +$12.7K | +13,346 | +41% |
|
|
MIH
3
Meitav Investment House
Bene-Beraq,
Israel
| $50.8K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $43.5K | +$32.6K | +34,280 | New |
|
|
5
Commonwealth Equity Services
Waltham,
Massachusetts
| $16K | +$12K | +12,625 | New |
|
6
Geode Capital Management
Boston,
Massachusetts
| $15.2K | – | – | – |
|
7
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| $1K | – | – | – |
|
|
AC
8
Armistice Capital
New York
| – | -$1.77M | -1,584,000 | Closed |
|
|
9
Morgan Stanley
New York
| – | -$1.68K | -1,500 | Closed |
|
|
10
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$60 | -54 | Closed |
|
NRSN Hedge Fund Activity: Q3 2024 in Review
7 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics (NRSN) for Q3 2024, worth a combined $286K — down 85% from $1.87M a quarter earlier.
Fund positioning in NRSN was balanced in Q3 2024: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $75.6K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.77M sold.
- 7 institutional investors held NeuroSense Therapeutics (NRSN) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $286K of NeuroSense Therapeutics stock for Q3 2024, down 85% quarter-over-quarter.
- 3 funds opened new NeuroSense Therapeutics positions in Q3 2024 and 3 closed out, a net change of 0 holders.
- The largest NeuroSense Therapeutics buyer in Q3 2024 was Cantor Fitzgerald, an estimated $75.6K added.
- The largest NeuroSense Therapeutics seller in Q3 2024 was Armistice Capital, an estimated $1.77M sold.
Based on aggregated 13F filings for Q3 2024.